VINORELBINE PIERRE FABRE vinorelbine 20mg (as tartrate) capsule blister pack

País: Austràlia

Idioma: anglès

Font: Department of Health (Therapeutic Goods Administration)

ingredients actius:

vinorelbine tartrate, Quantity: 27.7 mg (Equivalent: vinorelbine, Qty 20 mg)

Disponible des:

Pierre Fabre Australia Pty Ltd

formulario farmacéutico:

Capsule, soft

Composición:

Excipient Ingredients: ethanol; purified water; glycerol; macrogol 400; Gelatin; iron oxide yellow; titanium dioxide; medium chain triglycerides; sorbitol; 1,4-sorbitan; mannitol; hydrogenated starch hydrosylate; ascorbyl palmitate; phosphatidyl choline; dl-alpha-tocopherol; hypromellose; propylene glycol; isopropyl alcohol; aluminium chloride; sodium hydroxide; cochineal

Vía de administración:

Oral

Unidades en paquete:

1 tablet

tipo de receta:

(S4) Prescription Only Medicine

indicaciones terapéuticas:

Non-small cell lung cancer: VINORELBINE PIERRE FABRE is indicated for the first line treatment of advanced non-small cell lung cancer, as a single agent or in combination.,Breast cancer: VINORELBINE PIERRE FABRE is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.

Resumen del producto:

Visual Identification: Light brown soft capsule printed N20.; Container Type: Blister Pack; Container Material: PVC/PVDC/Al; Container Life Time: 3 Years; Container Temperature: Store at 2 to 8 degrees Celsius

Estat d'Autorització:

Licence status A

Data d'autorització:

2005-05-31